Key Takeaways
- Guidance intact despite a soft Q1: Revenue of ~₹120 crores was below the ₹160–170 crore quarterly run rate implied by the ₹650–675 crore full-year target, but management called the gap "only small variations" and reiterated both revenue and 18% margin guidance.
- The Hyderabad incident is still the binding constraint: Loss of 6,000 MT capacity forced the company to "limp back" across its other two plants, and Q1 utilization of ~77% reflects the slow, validation-heavy process of changing product mix after a disaster.
- Realization is doing the work: Average MCC realization rose to ₹241.36/kg from ₹216/kg in Q4, and management is deliberately balancing volume against higher-value grades that fetch ₹600–700/kg.
- Capacity-led recovery is the core thesis: The 12,000 MTPA Dahej-2 expansion, targeted for Q2 FY28, plus debottlenecking and a new CCS facility, is meant to restore market share lost to the capacity shortfall.
- What to watch next quarter: Whether Q2 API revenue actually improves on new molecules, whether the insurance claim lands by September, and whether utilization climbs quarter-on-quarter as promised.
The Hyderabad Incident and Its Aftermath
- Capacity loss: The company lost 6,000 MT of annual capacity at the Hyderabad facility, which forced customers with approved alternate suppliers to move volume elsewhere because they could not stop production.
- Why recovery is slow: The plant cannot turn around quickly after the incident; product-mix changes require shutdowns, start-overs, and cleaning validation, and these steps trade off against utilization, realization, and margin.
- Utilization snapshot: Q1 company-wide utilization was 76.8%, with Dahej at 76.5% and Jhagadia at 77.16%; management expects quarter-on-quarter improvement and plans debottlenecking to add capacity.
- Market share loss acknowledged: Management admitted losing share primarily due to the capacity shortfall, but said it is "quite hopeful" of regaining a bigger share of customer wallets once capacities return, citing relationships built over three decades.
- Insurance process: Assessment is complete and sent to the insurer; an e-auction has been initiated, and a few further reports were requested and will be submitted this week. Management expects either the full claim with some discount or an ad hoc amount before end of September.
- Insurance receivable: The company confirmed eligibility for ₹16.5 crores against the ₹25 crore business continuity policy, expected in another 3–4 months.
- Compensation: ₹42 lakhs was paid per deceased beneficiary, with the full amount provided in the books; management declined further comment citing sub-judice status and hopes there will be no further liability.
Amit Raj Sinha: "There is neither a supply side issue nor a market share issue. It is that the plant doesn't turn around so quickly. I wish it was like speeding up on a highway."
MCC Pricing and Product Mix
- Realization strength: Q1 average realization rose to ₹241.36/kg from ₹216/kg in Q4, with management noting a "good increase" quarter-on-quarter and continuously.
- Premium grades: Some MCC grades achieve realizations of ₹600–700/kg, so the company balances capacity utilization against higher-value product mix rather than maximizing volume alone.
- Entry barriers: Management pushed back on the perception that MCC is low-complexity, citing Aurobindo's Crest Cellulose venture incurring losses and being sold to Roquette as evidence that unproven players struggle with regulatory compliance and customer approval.
- Industry innovation: Management argued that formulators have shifted toward more sophisticated, innovative MCC grades over the last decade, which supports better pricing for differentiated products.
- Current trend: Current-quarter realization is "more or less same" as ₹241, with a gradual small increase expected by quarter-end and quarter-on-quarter improvement expected.
O.S. Reddy: "If they take this substandard or even unregulated or even those who is not proven in terms of their quality and customer satisfaction if they use, they may incur huge losses or the damage will be on higher side."
Capacity Expansion and New Facilities
- Dahej-2 MCC expansion: The 12,000 MTPA expansion is progressing on schedule, with commissioning targeted for Q2 FY28, taking total cellulose-based excipient capacity to 30,000 MTPA.
- CCS facility: The 1,800 ton Croscarmellose Sodium facility at Dahej SEZ is advancing, with operations expected in FY28 only.
- CCS export orientation: The planned CCS facility is oriented "more towards exports only," and the company is already receiving orders and inquiries from export customers before the facility is operational.
- CCS customer adoption: Management believes being an approved vendor in existing pharma supply chains will accelerate customer acquisition for CCS, since export customers who buy MCC also require CCS for the same applications.
- CCS margins: Management confirmed margins in the CCS segment can be assumed at 25% plus, even with CMC imported from China.
- CCS pricing: The company will work to price CCS "at the best point wherein customer is willing to pay."
- Debottlenecking: The company plans to add one shifter or some blender/small equipment and reduce idle time to increase production; by the time the 4,500 MT quarterly run rate is reached, theoretical capacity would have touched ~5,000 MT.
- Scaling confidence: Management believes utilization of the new facility can scale up much faster due to 30 years in the supply chain across 65 countries.
Amit Raj Sinha: "We believe that we can scale up the capacity utilization of the proposed new facility much faster, primarily because we have been in the supply chain for the last 30 years selling across 65 countries, selling the same product, established supply chain. So I don't believe that there is a challenge in that."
API Business
- Q1 performance: API revenue was around ₹21 crores, with management expecting improvement in Q2 and Q3.
- New molecules: Sparsentan, Zestrapin, and Bempedoic Acid are expected to drive higher revenues and margins; Sparsentan and Bempedoic Acid specifically carry higher margins.
- Full-year target: Management expects the API business to achieve more than ₹100–110 crores top line, "or even more than that also."
- Bempedoic Acid inventory: Management denied any inventory destocking issue, saying these are new molecules produced and sold based on orders, with no need to hold inventory.
- Cystic fibrosis product: Revenues expected "maybe next year" or "at the end of the year"; inquiries and orders are coming but current products fill capacities, with more clarity expected next quarter.
- Regulatory pipeline: The API business is supporting a CEP filing pipeline toward regulated market expansion.
- R&D status: API R&D capabilities are now fully operational.
Margins and Operating Leverage
- Q1 margin: EBITDA margin was 13%, well below the 18% full-year target.
- The bridge: Management expects margins to improve because fixed costs remain constant while revenues increase; indirect costs are expected to remain as-is, creating operating leverage.
- Q4 implied margin: An analyst's math implies Q4 margin must be higher than 20% to reconcile full-year 18% given Q1 at 13%; management confirmed this is possible once revenue goes up.
- Raw material efficiency: Efficiency improved and consumption was on the lower side, which supported margins; a slight positive variation was attributed to sales mix, with positive consumption expected in coming quarters.
- Receivables: Receivables days are coming down, currently at 93–94 days, with a year-end aim of ~90 days and an eventual target of 75–80 days.
Demand Environment
- MCC market outlook: The Asia Pacific region has historically grown at 7–8% CAGR, and reports indicate growth continuing at a reasonable pace, with the market expected to touch $1.4 billion by 2035.
- Smokeless tobacco demand: Management said the smokeless tobacco industry is nascent, with a shift from traditional smoking tobacco driving demand for cellulose MCC; nearly all supply is exported through distributors, with no direct visibility into end-use quantities.
- Smokeless tobacco growth: Management sees reasonable demand moving up from the shift to smokeless tobacco but cannot give future guidance; 30–40% growth is unrealistic to maintain, with a gradual taper to steady growth expected.
- CCS demand: Export customers who buy MCC also require CCS, since binder and disintegrant are used in the same application, driving inquiries.
- CCS market size: Management gave a value of $100 million and realization of ₹1,200–1,500 per kg, but did not provide tonnage directly.
Amit Raj Sinha: "I think that gradually, the smokeless tobacco industry would taper down and would have a steady growth. 30%-40%, is actually unrealistic to maintain."
Funding and Capital Allocation
- Capex plan: FY27 capex of more than ₹100 crores; FY28 capex of another ₹150–200 crores.
- Funding options: Management stated bankers are ready to provide loans; the company is currently debt-free with no term loan; a preferential issue or preferential warrants are under discussion but not finalized.
- Capital raise timing: Management deflected on timing, saying "at the appropriate time, once that is finalized, then we'll come with an announcement."
- Promoter open-market purchase: When asked whether the promoter is looking to buy from the open market considering the forfeiture of warrants, management deflected with "If anything is there, we'll make an announcement, sir."
- Prior warrant forfeiture: Management attributed the last forfeiture to "misplanning" at the last moment due to unexpected holidays, and said "hope every time it will not happen the same thing."
- Additional capex: Further capacity expansion in MCC and other areas is planned, with an announcement to come once finalized; the company increases MCC capacities every two years to meet customer demand.
O.S. Reddy: "Even last time that has some misplanning took place in the last moment because of unexpected holidays. And hope every time it will not happen the same thing."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue guidance | ₹650–675 crores, "more or less on track" | FY27 |
| EBITDA margin | 18% full-year target | FY27 |
| Dahej-2 MCC expansion | 12,000 MTPA commissioned, total capacity to 30,000 MTPA | Q2 FY28 |
| CCS facility | 1,800 ton facility to become operational | FY28 |
| Insurance claim | Full claim with some discount or ad hoc amount received | Before end of September |
| Insurance receivable | ₹16.5 crores expected | 3–4 months |
| API top line | More than ₹100–110 crores | FY27 |
| Utilization | Run rate beyond 95–96% as company gets closer to year-end | FY27 year-end |
| Q4 exit run rate | ~95% of 4,500 MT quarterly declared capacity, theoretical capacity ~5,000 MT by then | Q4 FY27 |
| Receivables | ~90 days by year-end, then 75–80 days | FY27 year-end / undated |
| Cystic fibrosis product revenue | "Maybe next year" or "at the end of the year" | FY27 end / FY28 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Total operating income | ₹121.27 crores |
| EBITDA | ₹16.5 crores, margin of 13.6% |
| Net profit | ₹8.14 crores, PAT margin of 6.76% |
| MCC segment revenue | ₹82.74 crores |
| API segment revenue | ₹21.68 crores |
| O&M segment revenue | ₹13.06 crores |
| Revenue guidance | ₹650–675 crores for FY27, no change confirmed |
| Full-year EBITDA margin guidance | 18%, management confirmed on track |
| MCC average realization | ₹241.36 per kg, up from ₹216 per kg in Q4 |
| Capacity utilization | 76.8% overall; Dahej 76.5%; Jhagadia 77.16% |
| Cellulose-based excipient capacity | 18,000 metric tons per annum, export share over 53.5% of production |
| Dahej-2 MCC expansion | 12,000 metric tons per annum, commissioning targeted Q2 FY28, taking total capacity to 30,000 metric tons per annum |
| Croscarmellose Sodium facility | 1,800 tons at Dahej SEZ, operational in FY28 |
| API full-year expectation | More than ₹100 crores to ₹110 crores, or even more |
| FY27 capex | More than ₹100 crores |
| FY28 capex | ₹150 crores to ₹200 crores |
| Receivables days | 93–94 days currently, target of 90 days by year-end, further target of 75–80 days |
| Insurance claim receivable | ₹16.5 crores eligible from business continuity policy of ₹25 crores, expected in 3–4 months |
| Compensation paid per deceased beneficiary | ₹42 lakhs each |